Beijing Vision Drugs Development

Beijing Vision Drugs Development is a private China-based drug development company focused on oncology and related medical technologies. Public corporate registry information identifies it as Beijing Vision Drugs Development Limited, with business activities covering anti-cancer, pharmaceutical, and food technology development, technology transfer, and consulting. Available evidence suggests the company has historically worked on sulfonamide-based anticancer compounds and is associated with the development of p-toluenesulfonamide injection, which was reported as approved in China in 2022 through the broader Jiandakang/Hongri Jiandakang group. The company appears to operate as a small, active private entity in Beijing rather than a broad platform biotech. Publicly accessible information on a broader pipeline, financing, partnerships, and commercial scale remains limited.